Non-alcoholic steatohepatitis (NASH) has emerged as a global health concern, affecting millions of individuals worldwide. NASH is a progressive liver disease characterized by inflammation and liver cell damage, often resulting from the accumulation of fat in the liver. According to DelveInsight’s evaluation in 2022, there were an estimated 21 million prevalent cases of NASH in the US. Out of these, a total of 9 million cases were diagnosed, and this number is projected to increase by the end of 2032 in the US. As the prevalence of NASH continues to rise, researchers and pharmaceutical companies are actively exploring innovative therapeutic approaches.
Available NAS...
